Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kintara Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KTRA
Nasdaq
8731
https://www.kintara.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kintara Therapeutics Inc
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
- Apr 4th, 2024 2:38 pm
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
- Apr 3rd, 2024 11:00 am
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
- Mar 27th, 2024 1:00 pm
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
- Feb 14th, 2024 9:07 pm
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
- Feb 12th, 2024 2:00 pm
Kintara Therapeutics Announces Review of Strategic Alternatives
- Dec 7th, 2023 2:00 pm
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
- Dec 5th, 2023 2:00 pm
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:10 pm
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
- Oct 31st, 2023 12:00 pm
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
- Oct 11th, 2023 12:00 pm
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
- Oct 2nd, 2023 12:00 pm
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
- Sep 25th, 2023 11:30 am
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
- Sep 18th, 2023 8:25 pm
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
- Sep 5th, 2023 12:00 pm
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
- Aug 17th, 2023 9:00 pm
Kintara Therapeutics to Present at the Emerging Growth Conference
- Aug 9th, 2023 12:16 pm
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
- Aug 8th, 2023 11:00 am
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.
- Jul 19th, 2023 12:00 pm
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
- Jun 30th, 2023 3:07 pm
Scroll